Literature DB >> 35104174

Knockdown of RNF183 suppressed proliferation of lung adenocarcinoma cells via inactivating the STAT3 signaling pathway.

Guangbin Ye1,2, Hongcheng Luo1, Tingting Zhang1, Tianshu Lan3, Bo Ling4, Zhongquan Qi1,3.   

Abstract

Proteins of the RNF183 (RING finger 183) family proteins have been reported to be of great importance in tumor the initiation and progression. However, the biological role and regulatory mechanism of RNF183 in non small cell lung cancer (NSCLC) development and progression are poorly defined. Hence, lung adenocarcinoma (LUAD) cell proliferation, cell apoptosis and cell cycle were measured using Cell Counting Kit-8 and flow cytometry analysis, respectively. The correlation between RNF183 and SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase) was measured using coimmunoprecipitation and ubiquitination analysis in vitro. Tumor growth of NSCLC cells in vivo was measured using the nude mouse xenograft model. In this study, we verify that elevated RNF183 expression in tumor tissues of LUAD, origin from the TCGA, GEPIA, TIMER, and UALCAN database. RNF183 regulates apoptosis and cell cycle in vitro and tumor growth in vivo by activating the STAT3 pathway through ubiquitination of SHP2, a negative feedback regulator of the STAT3 pathway. Taken together, our results demonstrate that RNF183 regulates proliferation, apoptosis, and cell cycle in LUAD cells via modulation of SHP2/STAT3 signaling, suggesting the potential for targeting the RNF183-SHP2/STAT3 pathway for use in LUAD treatment.

Entities:  

Keywords:  Lung adenocarcinoma; RNF183; STAT3; proliferation; ubiquitination

Mesh:

Substances:

Year:  2022        PMID: 35104174      PMCID: PMC9037501          DOI: 10.1080/15384101.2022.2035617

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   5.173


  31 in total

1.  The E3 ubiquitin ligase RNF182 inhibits TLR-triggered cytokine production through promoting p65 ubiquitination and degradation.

Authors:  Yang Cao; Yan Sun; Huiying Chang; Xin Sun; Shusen Yang
Journal:  FEBS Lett       Date:  2019-09-03       Impact factor: 4.124

Review 2.  The biology and management of non-small cell lung cancer.

Authors:  Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal:  Nature       Date:  2018-01-24       Impact factor: 49.962

Review 3.  Modes of allosteric regulation of the ubiquitination machinery.

Authors:  Martin L Rennie; Viduth K Chaugule; Helen Walden
Journal:  Curr Opin Struct Biol       Date:  2020-04-15       Impact factor: 6.809

Review 4.  Updated Review and Perspective on 20S Proteasome Inhibitors in the Treatment of Lung Cancer.

Authors:  Sagar O Rohondia; Zainab Sabry Othman Ahmed; Q Ping Dou
Journal:  Curr Cancer Drug Targets       Date:  2020       Impact factor: 3.428

Review 5.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

Review 6.  Ubiquitin signaling in immune responses.

Authors:  Hongbo Hu; Shao-Cong Sun
Journal:  Cell Res       Date:  2016-03-25       Impact factor: 25.617

7.  Genome-wide identification and gene expression profiling of ubiquitin ligases for endoplasmic reticulum protein degradation.

Authors:  Masayuki Kaneko; Ikuko Iwase; Yuki Yamasaki; Tomoko Takai; Yan Wu; Soshi Kanemoto; Koji Matsuhisa; Rie Asada; Yasunobu Okuma; Takeshi Watanabe; Kazunori Imaizumi; Yausyuki Nomura
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

8.  RNF115 promotes lung adenocarcinoma through Wnt/β-catenin pathway activation by mediating APC ubiquitination.

Authors:  Xiao-Ting Wu; Yu-Han Wang; Xiao-Yue Cai; Yun Dong; Qing Cui; Ya-Ning Zhou; Xi-Wen Yang; Wen-Feng Lu; Ming Zhang
Journal:  Cancer Metab       Date:  2021-01-28

9.  Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown.

Authors:  Nabendu Pore; Song Wu; Maria Libera Ascierto; Michael D Oberst; Nathan Standifer; Maria Jure-Kunkel; Melissa de Los Reyes; Yashaswi Shrestha; Rebecca Halpin; Raymond Rothstein; Kathy Mulgrew; Stephen Blackmore; Philip Martin; John Meekin; Matthew Griffin; Ina Bisha; Theresa A Proia; Ricardo J Miragaia; Ronald Herbst; Ashok Gupta; Shaad E Abdullah; Rajiv Raja; Melanie M Frigault; J Carl Barrett; Phillip A Dennis
Journal:  Cancer Discov       Date:  2021-07-06       Impact factor: 39.397

10.  CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.

Authors:  Henri Montaudié; Laura Sormani; Bérengère Dadone-Montaudié; Marjorie Heim; Nathalie Cardot-Leccia; Meri K Tulic; Guillaume Beranger; Anne-Sophie Gay; Delphine Debayle; Yann Cheli; Jérémy H Raymond; Pierre Sohier; Valérie Petit; Stéphane Rocchi; Franck Gesbert; Lionel Larue; Thierry Passeron
Journal:  J Invest Dermatol       Date:  2021-07-24       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.